Ongoing Phase 1b / 2 clinical trials combine entinostat with KEYTRUDA ® from Merck & Co., Inc. for non-small cell lung cancer, melanoma and colorectal cancer; with TECENTRIQ ® from Genentech, Inc. for triple negative breast cancer; and with BAVENCIO ® from Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.
In the interim analysis of this
ongoing multiple - dose
Phase 1b / 2a study, children with Type II or Type III SMA were dosed intrathecally with 3 mg, 6 mg or 9 mg of ISIS - SMNRx.